Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by:
MediciNova
ClinicalTrials.gov Identifier:
NCT01013142
First received: November 10, 2009
Last updated: March 30, 2010
Last verified: March 2010
  Purpose

The objective of this clinical study is to determine the safety of intravenous MN-221 compared to placebo when administered in subjects diagnosed with stable moderate to severe COPD.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: MN-221 (Dose Group 1)
Drug: MN-221 (Dose Group 2)
Drug: MN-221 (Dose Group 3)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I Randomized, Double-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously to Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:


Further study details as provided by MediciNova:

Primary Outcome Measures:
  • Adverse events, cardiac and ECG parameters, vital signs, physical exam and clinical laboratory assessments. [ Time Frame: Hour 0 (treatment) through Hour 24 (follow-up) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters of MN-221. [ Time Frame: Pre-dose to Hour 24 post-dose ] [ Designated as safety issue: No ]
  • Forced expiratory volume in one second (FEV1). [ Time Frame: Pre-dose to Hour 24 post-dose ] [ Designated as safety issue: No ]

Estimated Enrollment: 48
Study Start Date: November 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MN-221 Drug: MN-221 (Dose Group 1)
i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
Drug: MN-221 (Dose Group 2)
i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
Drug: MN-221 (Dose Group 3)
i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
Placebo Comparator: MN-221 Placebo Drug: MN-221 (Dose Group 1)
i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
Drug: MN-221 (Dose Group 2)
i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
Drug: MN-221 (Dose Group 3)
i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour

Detailed Description:

This is a randomized, double-blind, placebo-controlled, multi-center dose escalation study in subjects diagnosed with stable moderate to severe COPD. The study will be conducted in approximately 6 Clinical Research Units (CRUs).

Subjects with a diagnosis of stable moderate to severe COPD will be screened and must demonstrate an improvement in FEV1 after bronchodilator treatment of at least 12% at Screen Visit 1. The subject's degree of dyspnea will be captured on the British Medical Research Council (MRC) questionnaire, and severity will be determined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric criteria. Subjects meeting entry criteria at Screen Visit 1 will be asked to return to the CRU for Screen Visit 2 within 14 days of Visit 1. Subjects confirming entry criteria including degree of COPD severity by spirometry at Screen Visit 2 will be randomized to receive either MN-221 or placebo. Serial spirometry will be performed over the 8 hour treatment period after initiation of study drug administration. Subjects will be discharged from the CRU after completing the Hour 8 study procedures and asked to return approximately 24 hours after initiation of study drug for follow up safety assessments including spirometry. A study diary will be provided to each subject upon discharge from the CRU to complete as instructed and return it to the site at the 24 hour Follow-up Visit.

There will be three dose levels and each will include approximately 16 subjects randomized to receive either MN-221 or placebo in 3:1 ratio (12 subjects receive MN-221:4 subjects receive placebo). A risk/benefit evaluation will be performed by the study's Safety Review Committee at completion of each dose level prior to escalating to the next dose level.

Safety and efficacy will be monitored throughout the treatment period. Blood samples for PK parameters and metabolite identification will be obtained.

  Eligibility

Ages Eligible for Study:   40 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female 40-65 years of age, inclusive;
  2. History of physician-diagnosed COPD treated for ≥ 3 months ;
  3. FEV1 ≥ 30% < 80% and FEV1/FVC ratio < 0.7 at screening;
  4. An increase in FEV1 of at least 12%, over the pre-albuterol FEV1 within 30 minutes after inhalation of albuterol;
  5. Negative urine pregnancy test for all females unless the subject is post-menopausal (≥ 24 months of spontaneous amenorrhea) or surgically sterile (hysterectomy, bilateral ovariectomy or bilateral tubal ligation);
  6. Negative urine drug screen for cocaine, PCP, methamphetamine;
  7. ECG with no evidence of ischemic heart disease or dysrhythmias and otherwise normal or with findings considered not clinically significant at screening;
  8. QTcB and QTcF < 450 msec;
  9. No clinical evidence of active ischemic heart disease as determined by the Investigator; and
  10. Legally effective written informed consent obtained prior to starting any study procedures.

Exclusion Criteria:

  1. Beta agonist and/or anticholinergic via inhaler or intravenously ≤ 6 hours of screening;
  2. Sustained release methylxanthine (e.g. Theophylline) or long acting beta agonists ≤ 24 hours prior to screening;
  3. A diagnosis of clinically significant myocardial or valvular disease; including cardiomyopathy, congestive heart failure, or pulmonary edema;
  4. Acute exacerbation of COPD requiring emergency treatment ≤ 30 days of screening or hospitalization ≤ 90 days of screening;
  5. Antibiotic therapy for respiratory infection ≤ 30 days of screening;
  6. Presence of active respiratory disease such as pneumonia, or acute bronchitis;
  7. History or presence of tachyarrhythmias, with the exception of sinus tachycardia;
  8. Hypokalemia defined as a potassium level ≤ 3.0 mmol/L at screening;
  9. Significant renal, hepatic, endocrine, metabolic, neurologic or other systemic disease;
  10. Uncontrolled hypertension defined as a blood pressure ≥ 170/100 mm Hg at screening;
  11. Pregnant or lactating females;
  12. Participation in another clinical study with an investigational drug within 30 days of screening;
  13. A known allergy to excipients of the MN-221 drug product;
  14. A known allergy to other beta agonists;
  15. Previous exposure to MN-221; or
  16. Use of beta blockers, MAO inhibitors, or tricyclic antidepressants ≤ 2 weeks prior to screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01013142

Locations
United States, Arizona
Dedicated Phase I
Phoenix, Arizona, United States, 85013
United States, California
California Research Medical Group, INC
Fullerton, California, United States, 92835
United States, Florida
Vita Research Solutions & Medical Center, Inc.
Tamarac, Florida, United States, 33319
Florida Pulmonary Research Institue, LLC
Winter Park, Florida, United States, 32789
United States, Kansas
Vince and Associates Clinical Research
Overland Park, Kansas, United States, 66211
United States, Louisiana
Gulf Coast Research, LLC
Lafayette, Louisiana, United States, 70503
United States, Maryland
SNBL CLinical Pharmacology Center
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
MediciNova
Investigators
Study Director: Alan W Dunton, MD MediciNova
  More Information

No publications provided

Responsible Party: Alan W. Dunton, MediciNova
ClinicalTrials.gov Identifier: NCT01013142     History of Changes
Other Study ID Numbers: MN-221-CL-010
Study First Received: November 10, 2009
Last Updated: March 30, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by MediciNova:
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 22, 2014